此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Nilotinib Versus Standard Imatinib (400/600 mg Every Day (QD)) Comparing the Kinetics of Complete Molecular Response for Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Pts With Evidence of Persistent Leukemia by Real-time Quantitative Polymerase Chain Reaction (RQ-PCR)

2016年10月4日 更新者:Novartis Pharmaceuticals

An Open Label, Randomized Study of Nilotinib vs. Standard Imatinib (400/600 mg QD) Comparing the Kinetics of Complete Molecular Response for CML-CP Patients With Evidence of Persistent Leukemia by RQ-PCR.

The primary goal of this study was to determine the rate of confirmed best cumulative complete molecular response (CMR) within the first year of study therapy with imatinib or nilotinib. The study also explored the impact and significance of the achieved CMR on patient outcomes (progression free survival (PFS), event free survival (EFS) and overall survival (OS), characterized the kinetics of CMR achieved in both treatment arms and after the cross-over.

研究概览

研究类型

介入性

注册 (实际的)

207

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • British Columbia
      • Vancouver、British Columbia、加拿大、V5Z 1M9
        • Novartis Investigative Site
    • Ontario
      • Hamilton、Ontario、加拿大、L8H 4J9
        • Novartis Investigative Site
      • Toronto、Ontario、加拿大、M5G 2M9
        • Novartis Investigative Site
    • Quebec
      • Montreal、Quebec、加拿大、H1T 2M4
        • Novartis Investigative Site
      • Québec、Quebec、加拿大、G1J 1Z4
        • Novartis Investigative Site
    • MG
      • Belo Horizonte、MG、巴西、30130-100
        • Novartis Investigative Site
    • PR
      • Curitiba、PR、巴西、80060-900
        • Novartis Investigative Site
    • RJ
      • Rio de Janeiro、RJ、巴西、21941-913
        • Novartis Investigative Site
    • SP
      • Campinas、SP、巴西、13083-970
        • Novartis Investigative Site
      • Sao Paulo、SP、巴西、05403-000
        • Novartis Investigative Site
      • Bordeaux、法国、33076
        • Novartis Investigative Site
      • Creteil、法国、94010
        • Novartis Investigative Site
      • Lyon cedex 04、法国、69317
        • Novartis Investigative Site
      • Paris、法国、75010
        • Novartis Investigative Site
      • Vandoeuvre les Nancy、法国、54511
        • Novartis Investigative Site
    • New South Wales
      • St. Leonards、New South Wales、澳大利亚、2065
        • Novartis Investigative Site
      • Westmead、New South Wales、澳大利亚、2145
        • Novartis Investigative Site
    • Queensland
      • Herston、Queensland、澳大利亚、4029
        • Novartis Investigative Site
      • South Brisbane、Queensland、澳大利亚、4101
        • Novartis Investigative Site
      • Woolloongabba、Queensland、澳大利亚、4102
        • Novartis Investigative Site
    • South Australia
      • Adelaide、South Australia、澳大利亚、5000
        • Novartis Investigative Site
    • Victoria
      • Parkville、Victoria、澳大利亚、3050
        • Novartis Investigative Site
      • Prahran、Victoria、澳大利亚、3181
        • Novartis Investigative Site
    • Western Australia
      • Nedlands、Western Australia、澳大利亚、6009
        • Novartis Investigative Site
      • Madrid、西班牙、28006
        • Novartis Investigative Site
      • Madrid、西班牙、28007
        • Novartis Investigative Site
    • Andalucia
      • Malaga、Andalucia、西班牙、29010
        • Novartis Investigative Site
    • Cataluña
      • Barcelona、Cataluña、西班牙、08036
        • Novartis Investigative Site
    • Navarra
      • Pamplona、Navarra、西班牙、31008
        • Novartis Investigative Site
    • Buenos Aires
      • Caba、Buenos Aires、阿根廷、C1221ADH
        • Novartis Investigative Site

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

Diagnosis of chronic myeloid leukemia associated with BCR-ABL quantifiable by RQ-PCR Documented CCyR by bone marrow or BCR-ABL<1% IS in the past 12 months Persistent disease demonstrated by two PCR positive tests 3 months apart both during the past 6 months.

Treatment with imatinib for at least 2 years with 400 mg or 600 mg and a stable dose No other current or planned anti-leukemia therapies

Exclusion Criteria:

Patient has evidence of rising PCR (a confirmed >1 log increase in previous 6 months) Patient has received another investigational agent within last 6 months or tyrosine kinase inhibitors (TKIs) other than imatinib Prior allogeneic stem cell transplantation

Impaired cardiac function including any one of the following:

Inability to monitor the QT interval on electrocardiogram (ECG) Long QT syndrome or a known family history of long QT syndrome. Clinically significant resting brachycardia (<50 beats per minute) QTc > 450 msec on baseline ECG (using the QTcF formula). If QTcF >450 msec and electrolytes are not within normal ranges, electrolytes should be corrected and then the patient re-screened for QTc Myocardial infarction within 12 months prior to starting study Other clinically significant uncontrolled heart disease (e.g. unstable angina, congestive heart failure or uncontrolled hypertension) History of or presence of clinically significant ventricular or atrial tachyarrhythmias Administration of cytokine therapy (e.g. G-CSF, GM-CSF or SCF) within 4 weeks prior to study entry

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Nilotinib
Participants received Nilotinib 400 mg orally twice daily (bid) for 48 months.
Supplied in 200 mg capsules
有源比较器:Imatinib
Participants received Imatinib 400 mg or 600 mg once daily (qd) (based on the participant's dose prior to randomization) for 48 months.
Supplied in 100 mg and 400 mg capsules
其他名称:
  • 格列卫/格列卫

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Rate of Confirmed Best Cumulative Complete Molecular Response (CMR)
大体时间:12 months
The rate of confirmed best cumulative CMR was defined as the number of participants who had confirmed CMR during the first 12 months of treatment after the randomization date. Participants who achieved confirmed best cumulative CMR during the first 12 months were considered responders. Participants who dropped out early or who did not provide sufficient data for any reason were considered to be non-responders. The definition of CMR is undetectable BCR-ABL (fusion gene formed between bcr gene from chromosome 22 and abl gene from chromosome 9) where BCR-ABL ratio in % international scale (IS) ≤ 0.00001 by real-time quantitative polymerase chain reaction (RQ-PCR) where there was no detectable BCR-ABL and 1) the test had a sensitivity of at least 4.5 logs below the standardized baseline; 2) RQ-PCR negativity was confirmed on the next RQ-PCR sample (usually 3 months later); and 3) the date of confirmed CMR was the date of the first of two negative results with sensitivity >4.5 logs.
12 months

次要结果测量

结果测量
措施说明
大体时间
Rate of Confirmed Best Cumulative CMR
大体时间:24 months, 36 month, 48 months
The rate of confirmed best cumulative CMR was defined as the number of participants who had confirmed CMR during the 24, 36 and 48 months post treatment after the randomization date. Participants who achieved confirmed best cumulative CMR during the first 12 months were considered responders. Participants who dropped out early or who did not provide sufficient data for any reason were considered to be non-responders. The definition of CMR is undetectable BCR-ABL (fusion gene formed between bcr gene from chromosome 22 and abl gene from chromosome 9) where BCR-ABL ratio in % international scale (IS) ≤ 0.00001 by RQ-PCR where there was no detectable BCR-ABL and 1) the test had a sensitivity of at least 4.5 logs below the standardized baseline; 2) RQ-PCR negativity was confirmed on the next RQ-PCR sample (usually 3 months later); and 3) the date of confirmed CMR was the date of the first of two negative results with sensitivity >4.5 logs.
24 months, 36 month, 48 months
Number of Cross-over Participants With CMR
大体时间:24 months, 36 months, 48 months
The definition of CMR is undetectable BCR-ABL (fusion gene formed between bcr gene from chromosome 22 and abl gene from chromosome 9) where BCR-ABL ratio in % international scale (IS) ≤ 0.00001 by RQ-PCR where there was no detectable BCR-ABL and 1) the test had a sensitivity of at least 4.5 logs below the standardized baseline; 2) RQ-PCR negativity was confirmed on the next RQ-PCR sample (usually 3 months later); and 3) the date of confirmed CMR was the date of the first of two negative results with sensitivity >4.5 logs.
24 months, 36 months, 48 months
Progression Free Survival (PFS)
大体时间:48 months
PFS was defined as the time from the date of randomization to the date of the earliest documented progression-defining event as follows: transformation to blast crisis or accelerated phase disease, or death from any cause.
48 months
Event-free Survival
大体时间:48 months
Event-free survival was defined as the time from the date of randomization to the date of first occurrence of any of the following events on study treatment: loss of complete hematological response, confirmed loss of complete cytogenetic response (CCyR), confirmed loss of major molecular response (MMR), death from any cause during treatment, progression to the accelerated phase or blast crisis of chronic myelogenous leukemia (CML) per European Leukemia Network (ELN) criteria, whichever was earliest.
48 months
Overall Survival
大体时间:48 months
Overall survival was defined as the time from the date of randomization to the date of death due to any cause at any time during the study, including the follow-up period after discontinuation of treatment.
48 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2009年6月1日

初级完成 (实际的)

2015年7月1日

研究完成 (实际的)

2015年7月1日

研究注册日期

首次提交

2008年9月25日

首先提交符合 QC 标准的

2008年9月25日

首次发布 (估计)

2008年9月26日

研究记录更新

最后更新发布 (估计)

2016年11月8日

上次提交的符合 QC 标准的更新

2016年10月4日

最后验证

2016年10月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅